




# Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



August 1, 1997  
Volume 57 • Number 15  
PP. 3071-3324  
ISSN 0008-5472 • CNREA 8

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

# Angiogenesis and Cancer



January 24-28, 1998

Hyatt Orlando  
Orlando, FL

## CONFERENCE CO-CHAIRPERSONS

**Judah Folkman / Boston, MA**  
**Michael Klagsbrun / Boston, MA**

## CONFERENCE PROGRAM

### Keynote Address

**Nicole Le Douarin / Nogent sur Marne, France**

### Blood Vessels and Development

**Patricia D'Amore / Boston, MA**  
**Donald E. Ingber / Boston, MA**  
**Jeffrey M. Isner / Boston, MA**

### Mechanisms of Vasculogenesis and Angiogenesis

**Werner Risau / Bad Nauheim, Germany**  
**Peter Carmeliet / Leuven, Belgium**  
**Douglas Hanahan / San Francisco, CA**

### VEGF and VEGF Receptors

**Kari K. Alitalo / Helsinki, Finland**  
**Harold F. Dvorak / Boston, MA**  
**Napoleone Ferrara / S. San Francisco, CA**  
**Kenneth A. Thomas / West Point, PA**

### Angiopoietin and TIE Receptors

**George D. Yancopoulos / Tarrytown, NY**  
**Bjorn R. Olsen / Boston, MA**

### Tumor Angiogenesis and Metastasis

**Rakesh K. Jain / Boston, MA**  
**Robert S. Kerbel / Toronto, Ontario, Canada**  
**Isaiah J. Fidler / Houston, TX**  
**Ann F. Chambers / London, Ontario, Canada**

### Inhibitors of Angiogenesis

**Luisa Iruela-Arispe / Boston, MA**  
**Noël Bouck / Chicago, IL**  
**David A. Cheresh / La Jolla, CA**

### Clinical Applications

**Noel Weidner / San Francisco, CA**  
**Judah Folkman / Boston, MA**

### Additional Speakers to be Announced

**Application Deadline: October 13, 1997**

### Information and Application Forms:

American Association for Cancer Research  
Public Ledger Building, Suite 826  
150 South Independence Mall West  
Philadelphia, PA 19106-3483  
215-440-9300 215-440-9313 (FAX)  
E-mail: [aacr@aacr.org](mailto:aacr@aacr.org)  
Website: <http://www.aacr.org>

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

# Transcriptional Control of Proliferation, Differentiation, and Development



October 17-21, 1997

The Sagamore, Bolton Landing (Lake George), New York

## CONFERENCE CHAIRPERSONS

**Robert N. Eisenman** / Seattle, WA

**Elaine V. Fuchs** / Chicago, IL

## SCIENTIFIC PROGRAM

### Keynote Session

**Michael G. Rosenfeld** / San Diego, CA

**Stephen K. Burley** / New York, NY

**Michael R. Green** / Worcester, MA

### Transcriptional Mechanisms

**Richard A. Young** / Cambridge, MA

**Joan W. Conaway** / Oklahoma City, OK

**James L. Manley** / New York, NY

**Cynthia Wolberger** / Baltimore, MD

### The Influence of Chromatin Structure on Transcription

**Beverly M. Emerson** / La Jolla, CA

**Alan P. Wolffe** / Bethesda, MD

### Transcriptional Regulation of the Cell Cycle

**David M. Livingston** / Boston, MA

**Bruce A. Edgar** / Seattle, WA

**Charles J. Sherr** / Memphis, TN

**Erin K. O'Shea** / San Francisco, CA

### Signal Transduction and Transcription

**Gerald R. Crabtree** / Stanford, CA

**Joan Massague** / New York, NY

**Hans C. Clevers** / Utrecht, The Netherlands

### Oncogenic and Anti-Oncogenic Transcription Factors

**Carol Prives** / New York, NY

**A. Thomas Look** / Memphis, TN

**George F. Vande Woude** / Frederick, MD

**Robert N. Eisenman** / Seattle, WA

### Transcription Control of Differentiation

**David Baltimore** / Cambridge, MA

**Bruce M. Spiegelman** / Boston, MA

**Elaine V. Fuchs** / Chicago, IL

### Gene Manipulating Strategies

**Robb Krumlauf** / London, England

**Spyros Artavanis-Tsakonas** / New Haven, CT

**Eric N. Olson** / Dallas, TX

**Norbert Perrimon** / Boston, MA

*Applicants are encouraged to submit  
abstracts for poster presentation.*

---

### Information and Application Forms


American Association for Cancer Research  
Public Ledger Building, Suite 816

150 South Independence Mall West

Philadelphia, PA 19106-3483

215-440-9300 215-440-9313 (FAX)

E-mail: [aacr@aacr.org](mailto:aacr@aacr.org)



This issue's cover of *Cancer Research* is dedicated to Herbert D. Soule (top left), who played a leading role in the history of the Michigan Cancer Foundation (MCF), now named the Karmanos Cancer Institute.

Dr. Soule, a native of Salem, NH, and a descendant of one of the signers of the Mayflower Compact, received a B.S. degree in Biology (1949) and a M.S. degree in Microbiology (1952) from the University of New Hampshire. He received the Ph.D. degree from Wayne State University (WSU) in 1960.

Dr. Soule's scientific aptitude developed during his doctoral training in Cyril Stulberg's Cell Culture Laboratory at the current Children's Hospital of Michigan, where seminal work on cryopreservation of human cells and human cell line development was carried out. During his 39 years at the MCF, he developed the first hormone responsive human breast cancer cell line, MCF-7, and later the naturally immortalized human breast epithelial cell line, MCF-10, of which there are several sublines. Dr. Soule valued the willingness of individuals to provide tissue for research, although few patient samples have provided material as fruitful as MCF-7. Both Dr. Soule and the MCF-7 tissue donor, who was the last member of her family, left a legacy of hope to the scientific community and to cancer patients. The importance of Dr. Soule's accomplishments are manifest in the *Perspectives in Cancer Research* article by Anait S. Levenson and V. Craig Jordan in this issue (*Cancer Res.*, 57: 3071-3078, 1997). Many have benefited from the skill and fierce determination he exhibited in advancing knowledge in the field, even as he suffered from emphysema, a disease which plagued him for over ten years and resulted in his death on January 2, 1997.

Dr. Soule's patient and productive investigations were carried out with the continuous support of the MCF. The origins of cancer research at this organization date to 1941 when the Crocker Laboratory for Cancer Research at Columbia University was closing. Maynie Curtis took a valuable colony of inbred rats from the terminated laboratory to her family farm near Mason, MI, accompanied in this endeavor by her colleague, Wilhelmina Dunning. With the help of Rollin H. Stevens, then Head of the Department of Radiology of Grace Hospital and Chairman of the Cancer Committee of the Wayne County Medical Society, a laboratory was found for Drs. Curtis and Dunning in a building belonging to the WSU School of Medicine. Thus, the Detroit Institute of Cancer Research (DICR) was born and the now famous Dunning rats and prostate tumor line were preserved.

In 1945, the Southeastern Michigan Chapter of the American Cancer Society (ACS) and the community raised \$250,000 to purchase a building, which then became the DICR after remodeling under the direction of Harvey Marker of Parke-Davis. William L. Simpson was appointed Director in 1947. Title to the headquarters and laboratories was turned over to the newly created MCF in 1947 when the ACS decreed that none of its chapters could own property or operate clinics or laboratories. With further remodeling, these laboratories housed cancer studies for some 25 years.

During this period, Jerome P. Horwitz synthesized azidothymidine (AZT) in the DICR Chemistry Laboratory. Designed as an antitumor drug, it would become the first AIDS drug approved by the FDA two decades later. Two other AIDS drugs (ddC and d4t) were created by Dr. Horwitz in the late 1960s. In 1966, the DICR, the Yates Cancer Detection Clinic, and the Michigan Cancer Registry merged into the MCF. At this time, Michael J. Brennan, Chief of Medical Oncology at Henry Ford Hospital, was appointed President of the enlarged organization. In 1973, the MCF opened its new 120,000 square foot headquarters and laboratories (right), named after its major benefactor Meyer L. Prentis, the first Treasurer of the General Motors Corporation.

One of the initial accomplishments of the MCF was the establishment of the first hormone-dependent human breast cancer cell line, MCF-7, by Dr. Soule as described above. At this time, the cancer registry maintained by the MCF was invited to joining the NCI's SEER Program. Within a short period, WSU and the MCF created the Cancer Center of Metropolitan Detroit, which soon was designated a comprehensive cancer center by the National Cancer Institute (1978). This Center, which coordinated the efforts of over 100 investigators and clinicians, was initially directed by Dr. Brennan and later by Laurence Baker, who was appointed Director in 1988. Maintaining his devotion to research and breast cell culture, Dr. Soule culminated 5 years of effort in 1989 by developing the MCF-10 cell line, an immortalized nontumorigenic human breast epithelial line. These cells, which had not been exposed to viruses or carcinogens, have become a valuable model for the study of breast cell transformation. During this period, the experimental therapeutics group of the MCF discovered the anticancer activity of pyrazoloacridine (PZA) for use against solid tumors. Presently this agent is in national clinical trials.

Dr. Brennan retired in 1991 and was replaced as President by Vainutis Vaitkevicius, who brought about the merger of the MCF, the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit, and the cancer programs of WSU and the Detroit Medical Center, creating one of the country's largest centers dedicated to cancer research and treatment. The merger was followed by the completion of the Wertz Clinical Cancer Center (bottom left), which provides outpatient chemotherapy and houses multidisciplinary clinics and patient education programs.

After the retirement of Dr. Vaitkevicius, William Peters was recruited to head the newly combined center, which received a \$15 million gift from Peter Karmanos, Jr., to honor his late wife Barbara. As President and Chief Executive Officer of the Barbara Ann Karmanos Cancer Institute, Director of the Meyer L. Prentis Comprehensive Cancer Center at Metropolitan Detroit, and Associate Dean for Cancer Programs within WSU, Dr. Peters directs an organization with an operating budget of \$170 million, including \$27 million in grants and contracts, which supports the investigations of 140 scientists and clinicians and 61,000 patient encounters annually. The Karmanos Cancer Institute preserves the legacies of Dr. Soule, patient tissue donors, and the MCF by continuing to provide cell lines for research to investigators worldwide through its Cell Lines Resource.

We are grateful to Sam C. Brooks, Professor of Biochemistry and Molecular Biology, WSU School of Medicine, and Robert J. Pauley, Associate Professor, Karmanos Cancer Institute, for their assistance in coordinating the material for this cover feature.

Sidney Weinhouse